PNAX Stock Overview
Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Panaxia Labs Israel Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪81.16 |
| 52 Week High | ₪171.70 |
| 52 Week Low | ₪20.20 |
| Beta | -0.0013 |
| 1 Month Change | -32.70% |
| 3 Month Change | -33.26% |
| 1 Year Change | 15.61% |
| 3 Year Change | -95.90% |
| 5 Year Change | n/a |
| Change since IPO | -97.75% |
Recent News & Updates
Shareholder Returns
| PNAX | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -17.8% | 0.7% | 0.3% |
| 1Y | 15.6% | -16.0% | 11.6% |
Return vs Industry: PNAX exceeded the IL Pharmaceuticals industry which returned -16% over the past year.
Return vs Market: PNAX exceeded the IL Market which returned 11.6% over the past year.
Price Volatility
| PNAX volatility | |
|---|---|
| PNAX Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.4% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: PNAX's share price has been volatile over the past 3 months.
Volatility Over Time: PNAX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 59 | Dedi Segal | panaxia.co.il |
Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA – PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. The company was incorporated in 2005 and is based in Lod, Israel.
Panaxia Labs Israel Ltd Fundamentals Summary
| PNAX fundamental statistics | |
|---|---|
| Market cap | ₪12.15m |
| Earnings (TTM) | -₪13.40m |
| Revenue (TTM) | ₪19.59m |
0.6x
P/S Ratio-0.9x
P/E RatioIs PNAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNAX income statement (TTM) | |
|---|---|
| Revenue | ₪19.59m |
| Cost of Revenue | ₪25.41m |
| Gross Profit | -₪5.82m |
| Other Expenses | ₪7.58m |
| Earnings | -₪13.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -89.53 |
| Gross Margin | -29.72% |
| Net Profit Margin | -68.43% |
| Debt/Equity Ratio | -102.2% |
How did PNAX perform over the long term?
See historical performance and comparison